^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TGFBR1 (Transforming Growth Factor Beta Receptor 1)

    i
    Other names: TGFBR1, Transforming Growth Factor Beta Receptor 1, ALK-5, ALK5, ACVRLK4, TBR-I, TBRI, Activin A Receptor Type II-Like Protein Kinase Of 53kD, Transforming Growth Factor-Beta Receptor Type I, Activin A Receptor Type II-Like Kinase, 53kD, Serine/Threonine-Protein Kinase Receptor R4, Transforming Growth Factor Beta Receptor I, Activin Receptor-Like Kinase 5, TGF-Beta Receptor Type-1, TbetaR-I, TGFR-1, ESS1, MSSE, SKR4, Mutant Transforming Growth Factor Beta Receptor I, Multiple Self-Healing Squamous Epithelioma, TGF-Beta Type I Receptor, TGF-Beta Receptor Type I, LDS1A, LDS2A, AAT5, LDS1
    Associations

    News

    Trials
    11d
    Aloesin improves metabolic associated fatty liver disease and obesity by targeting TGFBR1. (PubMed, Phytomedicine)
    Aloesin improved lipid deposition and slowed the progression of MAFLD by targeting TGFBR1. The results support its potential application for the prevention and treatment of MAFLD.
    Journal
    |
    TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    20d
    Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome. (PubMed, Nat Aging)
    TGFBR1 inhibition with galunisertib or senolytic treatment reduces tumor progression driven by cisplatin-induced senescence, and concomitant use of TGFBR1 inhibitors with platinum-based chemotherapy reduces tumor burden and improves survival. Finally, we validate the translational relevance of tumor-promoting TGFβ-enriched SASP using clinical NSCLC and HGSOC samples from patients who received neoadjuvant platinum-based chemotherapy. Together, our findings identify a potential cancer therapy resistance mechanism and provide preclinical proof of concept for future trials.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    KRAS G12
    |
    cisplatin • galunisertib (LY2157299)
    24d
    Bile duct tumor thrombus (intraductal polypoid growth)-positive intrahepatic cholangiocarcinoma: clinicopathologic and genomic analysis. (PubMed, J Pathol)
    These results highlight the importance of evaluating BDTT in SDT, as it may be the main route of hilar extension in aggressive cases.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • MUC1 (Mucin 1) • SMAD4 (SMAD family member 4) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • MUC4 (Mucin 4, Cell Surface Associated) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2) • RSPO3 (R-Spondin 3) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • MUC17 (Mucin 17) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6) • PTPRK (Protein Tyrosine Phosphatase Receptor Type K) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 rearrangement
    1m
    Decoding adipocyte heterogeneity through single-nucleus transcriptomics unveils subtype-specific adipocytes orchestrate immunosuppressive niches in breast cancer. (PubMed, J Immunother Cancer)
    This study delineated a distinct adipocyte landscape in breast cancer and subtype-specific immunosuppressive niches fostered by CAAs and (pre-) adipocyte-macrophage interactions. These findings provide novel therapeutic targets for microenvironment-directed interventions in breast oncology.
    Journal
    |
    ER (Estrogen receptor) • LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    ER positive
    2ms
    TGF‑β at the Crossroads: Orchestrating the Bone Metastatic Microenvironment and Shaping Therapeutic Frontiers. (PubMed, Front Biosci (Landmark Ed))
    We outline pressing research priorities: mapping the spatiotemporal dynamics of TGF‑β activation, identifying predictive biomarkers for patient stratification, and engineering bone‑targeted delivery systems that preserve normal tissue repair. By decoding and disrupting the TGF‑β‑centered circuitry of bone metastasis, we can move closer to therapies that not only palliate skeletal complications but also prolong life for patients with advanced cancer.
    Review • Journal
    |
    LAG3 (Lymphocyte Activating 3) • TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2ms
    Multimodal biomarker landscape in vestibular schwannoma. (PubMed, Curr Opin Neurol)
    This review outlines emerging circulating, tissue-derived and imaging biomarker candidates in VS that may complement MRI and support more precise diagnosis, monitoring, and individualized management.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • MIR155 (MicroRNA 155) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MMP2 (Matrix metallopeptidase 2) • CCL11 (C-C Motif Chemokine Ligand 11) • MIR142 (MicroRNA 142) • MIR7 (MicroRNA 7) • CD80 (CD80 Molecule) • MMP14 (Matrix Metallopeptidase 14) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • S100B (S100 Calcium Binding Protein B)
    2ms
    PCAT7 Enhances Doxorubicin Resistance of Osteosarcoma by Modulating TGF-β Signalling. (PubMed, Folia Biol (Praha))
    These findings unveil a novel mechanism contributing to the constitutive activation of TGF-β signalling in osteosarcoma. Targeting PCAT7 may offer a promising avenue for therapeutic interventions in osteosarcoma by disrupting the aberrant TGF-β signalling, thus presenting a potential strategy to improve treatment outcomes in this challenging cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • MIR324 (MicroRNA 324) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    doxorubicin hydrochloride
    2ms
    TGF-β1-induced downregulation of the mitochondrial Ca2+ uniporter facilitates the migration of hepatic stellate cells. (PubMed, Biochem Biophys Res Commun)
    This study demonstrates that TGF-β1 suppresses MCU expression, revealing a previously unrecognized link between a profibrogenic cytokine and mitochondrial Ca2+ regulation. Furthermore, our results show that MCU loss enhances migration in non-malignant HSCs, extending observations that were previously limited to cancer cells.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2ms
    Identification and validation of ferroptosis-related key hub genes linking hypoxia and osteoporosis. (PubMed, BMC Musculoskelet Disord)
    In summary, we first screened ferroptosis-related key hub genes linking hypoxia and osteoporosis. The findings suggest that JUN, SQSTM1​, STAT3​ ​, CD44​​ and TGFBR1 are significantly associated with OP and hypoxia, potentially serving as biomarkers for diseases linked to ferroptosis. Additionally, hsa-miR-20a-5p was identified as a crucial upstream regulator likely involved in the regulation of these genes simultaneously.
    Journal
    |
    TP53 (Tumor protein P53) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • SQSTM1 (Sequestosome 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • JUN (Jun proto-oncogene) • MIR20A (MicroRNA 20a) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2ms
    Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model. (PubMed, Dent J (Basel))
    The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • MIR128 (MicroRNA 128) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2ms
    Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous Melanoma. (PubMed, Ann Surg Oncol)
    CP-GEP demonstrated good prognostic performance, particularly for patients with pT1b-pT2a melanoma and thus could be considered a noninvasive alternative for a SLNB.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • GDF15 (Growth differentiation factor 15) • MLANA (Melan-A) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • ITGB3 (Integrin Subunit Beta 3)
    |
    Merlin Assay